SCHEMBL592001

SCHEMBL592001

Cc1ccc(S(=O)(=O)OC2=NN(c3ncccc3Cl)C(C(=O)Nc3c(Br)cc(Cl)cc3C(=O)N(C)C3CC3)C2)cc1

nearest known ligand 0.34

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
MALT1 Q9UDY8 11/20 0.34
HSD11B1 P28845 1/20 0.33
FPR1 P21462 1/20 0.32
MAPT P10636 1/20 0.31
ENPP3 O14638 2/20 0.31
ENPP1 P22413 2/20 0.31
ENPP2 Q13822 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1148238 0.92 P2RY2 (0.31) MALT1
SCHEMBL591115 0.91 MALT1 (0.35) MALT1
SCHEMBL1148228 0.89 GPR17 (0.33) MALT1MAPTENPP3ENPP1
SCHEMBL1148351 0.88 MALT1 (0.32) MALT1MAPT
SCHEMBL1148273 0.86 MALT1 (0.36) MALT1MAPT
SCHEMBL592002 0.86 P2RX7 (0.36) MALT1HSD11B1
SCHEMBL591393 0.86 MALT1 (0.37) MALT1HSD11B1
SCHEMBL591460 0.85 MALT1 (0.33) MALT1HSD11B1
SCHEMBL591110 0.85 MALT1 (0.37) MALT1
SCHEMBL1148496 0.85 MALT1 (0.32) MALT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2093223-B1 PROCESS AND INTERMEDIATES FOR PRODUCTION OF AN ANTHRANILAMIDE COMPOUND ISHIHARA SANGYO KAISHA (JP) 2013-08-21 EP disclosed
US-8115006-B2 Process for producing anthranilamide compound ISHIHARA SANGYO KAISHA, LTD. (JP) 2012-02-14 US disclosed
US-20100063293-A1 PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND ISHIHARA SANGYO KAISHA ,LTD. (JP) 2010-03-11 US disclosed
EP-2093223-A1 PROCESS FOR PRODUCTION OF ANTHRANILAMIDE COMPOUND ISHIHARA SANGYO KAISHA, LTD. (JP) 2009-08-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063293-A1 PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND NAAA, AAAS, AADAC MALT1 1682/4885HSD11B1 899/4885FPR1 2780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.